Esperion Therapeutics Q1 EPS $0.34 Beats $0.05 Estimate, Sales $137.74M Beat $84.51M Estimate
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics (NASDAQ:ESPR) reported Q1 earnings of $0.34 per share, surpassing the $0.05 estimate, a 143.04% increase from last year's losses. Sales reached $137.74M, beating the $84.51M estimate, marking a 466.14% increase from the previous year.
May 07, 2024 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics reported a significant beat on both earnings and sales estimates for Q1, with earnings per share at $0.34 against a $0.05 estimate and sales of $137.74M against an $84.51M estimate.
The substantial beat on both earnings per share and sales estimates for Esperion Therapeutics indicates a strong financial performance and operational efficiency, likely leading to positive investor sentiment and a potential increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100